Rybelsus contains the active ingredient semaglutide. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. (A drug class is a group of medications that work in a similar way.) ...

Rybelsus (semaglutide) is a prescription drug that’s used to manage blood sugar levels in adults with type 2 diabetes. Rybelsus comes as a tablet that you’ll swallow with a little water each day.

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

while the University of Colorado has an ongoing 135-patient trial of oral semaglutide (Rybelsus) in people seeking treatment for AUD. Novo Nordisk itself, meanwhile, recently started a phase 2 ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% ...